Brean Murray Cuts Encysive Pharma to Hold

Analyst Jonathan Aschoff notes the FDA's recent request for more clinical trial work researching the drug Thelin

Brean Murray downgraded Encysive Pharmaceuticals (ENCY to hold from accumulate, citing the Food and Drug Administration's recent request for more clinical trial work researching the drug Thelin.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.